Digest Network Come funziona
Network
/
Società
Bl
Non verificato

Blue Lake Biotechnology, Inc.

Di cosa scriviamo

FarmaceuticaHIV, AIDS e malattie autoimmuniIndustriaMedicina - VarieSalute

6 comunicati stampa

Guarda tutti i comunicati
21/11/2025
Igiene alimentare
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Blue Lake Biotechnology to Resume Enrollment of RSV-negative Toddlers in Phase 1/2a Clinical Trial of BLB201
Fonte
Blue Lake Biotechnology, Inc.
Emittente
Business Wire
1.00
0
07/07/2025
Scienza
Biotecnologia
Farmaceutica
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Industria
Blue Lake and CyanVac Publish Full Data from Open Label Phase 1 Clinical Study of COVID-19 Vaccine Candidate
Fonte
Blue Lake Biotechnology, Inc.
Emittente
Business Wire
1.00
0
10/03/2025
Eventi
Industria
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Blue Lake Biotechnology to Present Safety and Immunogenicity Data for its RSV Intranasal Vaccine Candidate at the 13th International RSV Symposium
Fonte
Blue Lake Biotechnology, Inc.
Emittente
Business Wire
1.00
0
12/12/2024
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Blue Lake Biotechnology Reports Additional Promising Clinical Data from Ongoing Pediatric Clinical Study of Intranasal RSV Vaccine BLB201
Fonte
Blue Lake Biotechnology, Inc.
Emittente
Business Wire
1.00
0
25/11/2024
Industria
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Blue Lake and CyanVac Report Positive Phase 2a Data for Intranasal COVID-19 Vaccine Candidate
Fonte
Blue Lake Biotechnology, Inc.
Emittente
Business Wire
1.00
0
21/10/2024
Multimedialità
Industria
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Blue Lake Biotechnology and CyanVac Announce Presentation on Intranasal Vaccine Candidates at the International Society for Vaccines Annual Congress
Fonte
Blue Lake Biotechnology, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0